Registrieren
Registierung erfolgt in Kürze...
Details werden geladen...
Regeneron's Phase 3 skin cancer miss adds to mounting failures in LAG-3
Regeneron Pharmaceuticals’ LAG-3 inhibitor called fianlimab has flunked a late-stage skin cancer trial, marking yet another blow for the drug class.
Ähnliche Seiten
BioMarin's rare disease therapy shows no clinical benefit in Phase 3 test
https://endpoints.news/biomarins-rare-disease-therapy-shows-no-clinical-benefit-in-phase-3-test/
Regeneron, Parabilis set out to create new drug class in deal worth up to $2.3B - BioSpace
https://www.biospace.com/deals/regeneron-parabilis-set-out-to-create-new-drug-class-in-deal-worth-up-to-2-3b
Nanobiotix Announces Presentation of Part 1 Data From a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer | The Manila Times
https://www.manilatimes.net/2026/05/17/tmt-newswire/globenewswire/nanobiotix-announces-presentation-of-part-1-data-from-a-randomized-phase-2-clinical-trial-evaluating-jnj-1900-nbtxr3-in-stage-3-inoperable-lung-cancer/2345706
Iconic Singer Barry Manilow to Undergo a Procedure for Cancer in His Lung.
https://weltblicke.at/iconic-singer-barry-manilow-to-undergo-a-procedure-for-cancer-in-his-lung/Antengene Appoints Dr. Bing Hou as Chief Scientific Officer to Lead Innovation-Driven R&D Strategy and Advance Next-Generation Pipeline | The Manila Times
https://www.manilatimes.net/2026/05/20/tmt-newswire/pr-newswire/antengene-appoints-dr-bing-hou-as-chief-scientific-officer-to-lead-innovation-driven-rd-strategy-and-advance-next-generation-pipeline/2347746